Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-
cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or …

Purpose: This multicenter, phase II study evaluates the efficacy and safety of erlotinib, an
epidermal growth factor receptor (EGFR) inhibitor, plus sorafenib, a multityrosine kinase …

Purpose Sorafenib is an oral multikinase inhibitor that targets the Ras/Raf/MEK/ERK
mitogenic signaling pathway and the angiogenic receptor tyrosine kinases, vascular …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Introduction Sorafenib monotherapy has shown benefits in phase II trials as third-/fourth-line
treatment in patients with non-small-cell lung cancer (NSCLC). Methods The phase III …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …